Ruxolitinib

Generic Name: Ruxolitinib

Brand Names: Jakafi, Jakavi, Opzelura

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈N_₆

CAS Number: 941678-49-5

Unique Ingredient Identifier: 82S8X8XX8H

Background: Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...

Indication: Ruxolitinib is indicated for the treatment of the following conditions:

Topical ruxolitinib is indicated for:

Associated Conditions: Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera

Associated Therapies: -

Clinical Trials

Ruxolitinib Pre-, During- and Post-HSCT for Patients with Primary or Secondary Myelofibrosis.

Phase 2

Active, not recruiting

Conditions: Myelofibrosis

Interventions: Drug: Ruxolitinib

First Posted Date: 2018-02-09

Last Posted Date: 2024-11-20

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 44

Registration Number: NCT03427866

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

and more 2 locations

Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

Phase 1

Terminated

Conditions: Myelofibroses

Interventions: Drug: Pevonedistat
Drug: Ruxolitinib
Procedure: Peripheral blood draw
Procedure: Skin biopsy

First Posted Date: 2017-12-29

Last Posted Date: 2022-01-06

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 8

Registration Number: NCT03386214

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Phase 1

Terminated

Conditions: Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Myelofibrosis

Interventions: Drug: PU-H71
Drug: Ruxolitinib

First Posted Date: 2017-12-14

Last Posted Date: 2022-11-15

Lead Sponsor: Samus Therapeutics, Inc.

Target Recruit Count: 4

Registration Number: NCT03373877

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States

and more 7 locations

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia
Acute Myeloid Leukemia in Remission
Allogeneic Stem Cell Transplantation

Interventions: Drug: Ruxolitinib

First Posted Date: 2017-09-18

Last Posted Date: 2024-03-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 64

Registration Number: NCT03286530

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States

and more 3 locations

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Phase 2

Active, not recruiting

Conditions: Myelofibrosis (MF)

Interventions: Drug: Navitoclax
Drug: Ruxolitinib

First Posted Date: 2017-07-19

Last Posted Date: 2024-06-27

Lead Sponsor: AbbVie

Target Recruit Count: 191

Registration Number: NCT03222609

Locations: 🇺🇸
University of Southern California /ID# 164095, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute /ID# 162675, Boston, Massachusetts, United States
🇨🇦
Princess Margaret Cancer Centre /ID# 214483, Toronto, Ontario, Canada

and more 88 locations

Ruxolitinib in Operable Head and Neck Cancer

Phase 2

Terminated

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Ruxolitinib

First Posted Date: 2017-05-15

Last Posted Date: 2024-10-30

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 16

Registration Number: NCT03153982

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Conditions: Graft-versus-host Disease (GVHD)

First Posted Date: 2017-05-10

Last Posted Date: 2022-06-07

Lead Sponsor: Incyte Corporation

Registration Number: NCT03147742

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Rutgers Cancer Institute, New Brunswick, New Jersey, United States
🇺🇸
Texas Oncology, Dallas, Texas, United States

and more 30 locations

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Phase 2

Completed

Conditions: MPN (Myeloproliferative Neoplasms)

Interventions: Drug: Itacitinib
Drug: Ruxolitinib

First Posted Date: 2017-05-09

Last Posted Date: 2022-06-16

Lead Sponsor: Incyte Corporation

Target Recruit Count: 23

Registration Number: NCT03144687

Locations: 🇺🇸
Texas Oncology - Tyler, Tyler, Texas, United States
🇦🇹
Paracelsus Medical University Salzburg, Salzburg, Austria
🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

and more 22 locations

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Phase 2

Terminated

Conditions: MPN (Myeloproliferative Neoplasms)

Interventions: Drug: Ruxolitinib
Drug: Anagrelide
Drug: Placebo

First Posted Date: 2017-04-21

Last Posted Date: 2021-11-19

Lead Sponsor: Incyte Corporation

Target Recruit Count: 12

Registration Number: NCT03123588

Locations: 🇺🇸
Columbia Weill Cornell Cancer Centers - Herbert Irving Comprehensive Cancer Center (HICCC), New York, New York, United States
🇺🇸
Ventura County Hematology-Oncology Specialists, Oxnard, California, United States
🇺🇸
Tift Regional, Tifton, Georgia, United States

and more 23 locations

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

First Posted Date: 2017-04-18

Last Posted Date: 2024-11-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 790

Registration Number: NCT03117751

Locations: 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸
St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺
The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy